Patheon's Innovations Focus On Solving Bioavailability Issues
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its new services dedicated to bioavailability issues at the AAPS Annual Meeting and Exposition in Chicago, Illinois.
Improving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Two years ago, Patheon launched SoluPath®, an innovative and cost-effective service to identify an optimal drug delivery system for compounds with poor bioavailability. Through a parallel screening approach of technologies such as solid dispersions, microparticles or lipid-based formulations, the program has allowed a consistent 3X to 5X increase of bioavailability and shows 30% save rate for compounds that would have failed due to bioavailability issues. The company has recently added HME to the range of technologies utilized by the SoluPath® program.
Patheon also launched a new line of softgel solutions that opens the door to an array of bioavailability enhancing formulation strategies such as Self-Emulsifying Drug Delivery Systems (SMEDDS/SEDDS), Concentrated Micro-Emulsion Technology, Galenic system that mixes hydrophilic and lipophilic phases, or Micro-Particle Technology.
Patheon representatives will be available to meet at the AAPS Annual Meeting and Exposition in Chicago, Illinois on October 14-18, 2012.
To schedule an interview with Patheon during or after the conference, please contact Jennifer Almond at media(at)Patheon(dot)com.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of solid and sterile dosage forms, including softgels.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of nine manufacturing facilities and nine development centers across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
View original release here: http://www.prweb.com/releases/2012/10/prweb10015686.htm